Elan Weiner,
Founder and CEO

Elan Weiner is an American Society of Clinical Pathology licensed specialist in blood banking, and a strategic healthcare leader with extensive experience in transfusion medicine, blood safety, biologics development, product commercialization, and market expansion. He has spent his career focusing on the safety and availability of blood, and blood-derived drugs. Elan has patented, developed, and brought to market blood-based drugs used in the treatment of bleeding, including massive hemorrhage, and Thrombotic Thrombocytopenic Purpura (TTP). Prior to joining ECI Therapeutics, Elan most recently served as Vice President of Business Development, and General Manager of Global Therapeutics at Cerus Corporation where he stood up and led a new Business Unit, successfully shepherding biologics from concept through approval, commercialization, and market expansion. Elan has published extensively on topics within blood and cell therapy, has served on national and international committees at AABB (formerly American Association of Blood Banks), and ISBT (International Society of Blood Transfusion), and has served on the board of 2 healthcare not for profit organizations. Elan brings extensive executive leadership, personnel recruitment and management, strategic planning, P&L, commercialization, regulatory, compliance, clinical trial, reimbursement, CMC, supply chain, and transfusion medicine expertise to ECI Therapeutics.

Follow Elan on LinkedIn

Ronald C. Gentile,
Founder and CMO

While practicing Ophthalmology, Dr. Gentile recognized an unmet need: patients suffering—sometimes to a debilitating degree—from dry eye disease and inadequate treatment options available to them. This observation and his knowledge that better treatments are possible led him to become the organizing force behind ECI Therapeutics.

Ronald C. Gentile MD, FACS, FASRS is a Clinical Professor of Ophthalmology affiliated with NYU Langone Health, New York Eye and Ear Infirmary (NYEEI), and SUNY School of Optometry in NYC. He also has affiliations on Long Island with NYU Winthrop University Hospital and NYU Long Island School of Medicine. Dr. Gentile dedicates his time to clinical ophthalmic care, surgery, research, teaching, and humanitarian work. He is a retinal specialist and surgeon with expertise in diabetic eye disease, macular diseases, retinal detachments and ocular trauma.

After graduating at the top of his class at the School of Medicine at SUNY Downstate in Brooklyn, he completed his internship at Columbia Presbyterian Medical Center and his ophthalmology residency at the New York Eye and Ear Infirmary. He performed his Retina Fellowship at the prestigious Kresge Eye Institute in Detroit, Michigan. Following fellowship, he was recruited back to NYC were he quickly rose through the ranks from assistant professor to full professor within 12 years.

Dr. Gentile has been consistently listed as one of Best Doctors in New York (Castle Connolly Medical Ltd.) and New York Super Doctors®, recommended by his peers. He has received dozens of awards and honors including the Richard T. Troutman, MD, Award in Ophthalmology, the American Academy of Ophthalmology’s Achievement Award, and the American Society of Retina Specialists (ASRS) Honor Award. He has been and continues to be a principal investigator for many trials and he has over a hundred publications.

He has been involved in leading humanitarian missions to India, Africa, Nepal, and Latin America and is founding member of Operation Restore Sight, a humanitarian organization that leads international eye care missions to restore vision to the poor and train local eye care physicians in underserved communities.

Follow Ronald on LinkedIn

Matthew Dowling,
Founder and VP Research

Matthew Dowling, Ph.D., is Chief Scientific Officer and Director of Medcura. Matt completed his graduate work at the Fischell Department of Bioengineering, after completing his undergrad in chemical engineering from the University of Notre Dame. At UMD, he was awarded the Fischell Fellowship in Biomedical Engineering for his innovative ideas in drug delivery systems. Matt then co-created gel-e, a novel biomaterial platform, raising several initial grants to develop the technology and to launch Medcura as a corporate entity. Matt was the recipient of the Dean’s Doctoral Research Award from the UMD Clark School of Engineering for his work on chitosan-based self-assembled soft materials for use in wound treatment. He has been the Principal Investigator on multi-million dollar grants; these have been used to achieve five FDA clearances, eight issued patents, 10+ peer-reviewed publications in high-impact journals and a commercial partnership with one of the world’s largest pharmacy retailers. Matt’s work has been featured on several U.S. and international media outlets including the BBC TV program, Brave New World with Stephen Hawking.

Follow Matthew on LinkedIn

Lloyd Hildebrand,
Founder and Chairperson,
Board of Directors

Dr. Hildebrand is a seasoned clinician and serial entrepreneur. He is an academic ophthalmologist and educator with specialty training in ophthalmic plastic and reconstructive surgery in a broad clinical practice. He graduated from the University of Manitoba College of Medicine and practiced as a family physician for nine years before pursuing specialty training in ophthalmology and ophthalmic plastic and reconstructive surgery at the University of Oklahoma’s Dean McGee Eye Institute, and Oregon Health Sciences University in Portland, Oregon respectively. He is Professor Emeritus at the University of Oklahoma’s Dean McGee Eye Institute where he has worked since 1994, partially retiring from that surgical practice in 2016 to pursue entrepreneurial activities. He graduated from the Physician CEO program at Kellogg School of Management in 2015. He has led large multi-specialty practices as well as startup and medical technology companies; held leadership roles in numerous professional organizations; is experienced in international ophthalmology; is knowledgeable in design and conduct of research trials, regulatory affairs; has expertise in policy, reimbursement and IT; and extensive executive level experience. He currently maintains an oculoplastic surgery practice at Comprehensive Eye Care in Las Vegas, NV and is a Clinical Professor at the UNLV Kerkorian School of Medicine.

Follow Lloyd on LinkedIn